// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























169 Abstracts

Sarcopenia Strongly Affects Serum Levels of Cystatin C in Patients with Heart Failure

J. Ivey-Miranda - Heart Failure Society of America (HFSA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Congestive heart failure

N/A

Association of Leptin with Cystatin C in Kidney Allograft Dysfunction

A. Bera - American Transplant Congress (ATC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

MEF75, MEF25-75 and Serum Cystatin C Are Predictors of Chronic Obstructive Pulmonary Disease in Adults

D. Feng - American Thoracic Society (ATS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Higher Plasma Cystatin C Is Associated with Mortality After ARDS

C. M. Hendrickson - American Thoracic Society (ATS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Comparison of the Tolvaptan Versus Furosemide-Based Diuretic Regimes in Patients Hospitalized for Heart Failure with Hyponatremia (AQUA-AHF)

Tien M. Ng - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

furosemide GR

Risk Stratification in HFPEF Patients According to eGFR Level Derived From CKD-EPI Equations with or Without Serum Cystatin C Inclusion

Tatiana Nikiforova - Heart Failure Society of America (HFSA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Risk of death and cardiovascular events among patients presenting with acute coronary syndrome: the evolving role of cystatin C, NGAL and galectin-3 as prognostic biomarkers

D.N. Nanchen - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Methadone hydrochloride

Biomarkers of kidney injury, vascular stiffness and kidney fibrosis in gender subgroups of hypertensive patients

S.A. Mironova - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Markers of acute kidney injury in patients with acute decompensated heart failure in the assessment methods decongestion

I. Gorda - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

furosemide GR

Cystatin C and neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of TAVI associated acute kidney injury

G.F. Filardo - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Health Behaviors in Younger and Older Adults With CKD: Results From the CRIC Study

Sarah J. Schrauben - International Society of Nephrology (ISN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Population-Based Incidence of Paediatric AKI in a Low Middle-Income Country using Serum Cystatin C and Creatinine

M. Alao - International Society of Nephrology (ISN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

N/A

ASSESSMENT OF RENAL FUNCTION IN MOTOR COMPLETE SPINAL CORD INJURY PATIENTS – CYSTATIN C AS AN ACCURATE SINGLE MARKER

T.A. AUGUSTINE - International Society of Nephrology (ISN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Traumatic spinal cord injury

N/A

THE COMPARISON OF MEASURED GFR WITH EXISTING EGFR EQUATIONS IN HEALTHY INDIAN POPULATION

P.K. Johal - International Society of Nephrology (ISN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Omnipaque 350

RISK FACTORS ASSESSMENT IN PROGRESSION OF SNAKE VENOM INDUCED ACUTE KIDNEY INJURY TO CHRONIC KIDNEY DISEASE

P. MUKHOPADHYAY - International Society of Nephrology (ISN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

Moderate Impairment in Kidney Function Is Correlated to Changes in Cardiac Function and Structure

AndersChristensson - American Society of Nephrology (ASN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Role of Plasma Cystatin C and Urine NGAL in Prediction of AKI and Mortality in Patients with Acutely Decompensated Cirrhosis: A Prospective Cohort Study

Sang-KyungJo - American Society of Nephrology (ASN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

TIMP-2

Utility of Serum Cystatin C (SCysC) to Assess AKI and Day 90 (D90) Major Kidney Adverse Events (MAKE90) Following Cardiac Surgery (CS) in Subjects Treated with QPI-1002

LukasJ.Lehner - American Society of Nephrology (ASN) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

QPI 1002

Proteomic Analysis of Perfusate from Machine Cold Perfusion of Transplant Kidneys: Comparison Between Circulatory and Neurological Death

AndreaAngeletti - American Society of Nephrology (ASN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Serum Cystatin C Is a Significant Marker of Early Glomerular and Tubular Interstitial Lesions in Patients with Primary Glomerulonephritis: Results from Single Center Cross-Sectional Single-Blind Study

ElenaSaganova - American Society of Nephrology (ASN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Prednisolone

Copyright © 2026. QuantiNova All rights reserved